Swiss Tropical and Public Health Institute AT A GLANCE · The project is funded by the Swiss Agency...
Transcript of Swiss Tropical and Public Health Institute AT A GLANCE · The project is funded by the Swiss Agency...
AT A GLANCE Swiss Tropical and Public Health Institute
‘THERE IS NO FIRST, SECOND OR THIRD WORLD. THERE IS ONLY ONE WORLD.’
Marcel Tanner, Director Swiss TPH (1997 – 2015)
Swiss TPH is active in the following countries:
Albania ArmeniaAustraliaAzerbaijanBelgiumBeninBhutan Bosnia / HerzegovinaBrazil Burkina FasoBurundiCambodiaCameroonCentral African RepublicChad China Côte d’IvoireDenmarkDjiboutiDR CongoEgyptEl Salvador
Equatorial GuineaEstoniaEthiopiaFinlandFranceGabonGambiaGeorgiaGermanyGhanaGreece GuatemalaGuineaHungaryIcelandIndiaIndonesiaIsraelJapanKazakhstanKyrgyzstanLao PDRLatviaLiechtenstein
Malawi MalaysiaMaliMauritaniaMexicoMoldova MongoliaMozambiqueMyanmarNamibiaNepalNetherlandsNicaraguaNigerNigeriaNorwayPakistanPalestinian territories Papua New GuineaPeruPhilippinesPolandRomania
RussiaRwandaSao Tomé SenegalSierra LeoneSloveniaSouth Africa SpainSri LankaSwedenSwitzerlandSyriaTajikistanTanzaniaTogoThailandUgandaUkraine VietnamZambiaZimbabwe
Home office locations around the world
714staff members
from
62nations
Swiss Tropical and Public Health Institute (Swiss TPH) is a world-leading institute in health research, training and services. It improves, maintains and promotes the health of individuals and societies in Switzerland and all around the globe. A special emphasis is on resource-constrained countries.
‘TOGETHER, WE CAN MAKE A DIFFERENCE.’
Jürg Utzinger, Director Swiss TPH (from July 1st, 2015)
590staff members and students
working in Basel, Switzerland
124staff members
working in
20nations
Swiss TPH provides health advisory to national and international organisations, health systems support, eHealth or training courses.
Towards the Elimination of Malaria
The Roll Back Malaria Partnership (RBM) has contracted Swiss TPH and Deloitte Con-sulting LLP to guide the second generation Global Malaria Action Plan (2016 – 2025). This plan will serve as an advocacy instru-ment to achieve a malaria-free world.
‘HEALTH PROGRESS IS ONLY FEASIBLE IF WE ALSO IMPROVE INFRASTRUCTURE, INFORMATION TECHNOLOGIES AND THE SKILLS OF HEALTH WORKERS.’
Kaspar Wyss, Deputy Head, Swiss Centre for International Health
SERVICES IN DEMAND
Insecticide-treated nets reduce malaria burden in Africa.
Swiss TPH • Strategic Goals
Understanding diseases and
improving health systems
Swiss Centre for International Health
The Swiss Centre for International Health (SCIH) at Swiss TPH offers consultancy, evaluation and advisory services on national and global health issues. National and international or-ganisations choose SCIH because of the distinguished expertise and long-term experience in the field of international health. Key clients include the World Health Organisation (WHO), the World Bank (WB), the Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM) and the Swiss Agency for Development and Cooperation (SDC).
eHealth for Preventive Medicine in Switzerland
The EviPrev-Programme provides evidence- based knowledge on preventive medicine for general practitioners. Swiss TPH has developed an electronic decision support system. It includes electronic patient re-cords, individualised risk assessment tools and guidelines for disease prevention. The eHealth system is an important step to reach the ‘principle of informed choice’.
Health Coverage for All
Swiss TPH designed and implemented a new health insurance scheme for the rural Tanzanian population. For the equivalent of five Swiss francs a whole family can profit from basic health care coverage during one year. The project is funded by the Swiss Agency for Development and Cooperation (SDC) and contributes to the goal of universal health coverage.
Swiss TPH unites health professionals with various academic and non-academic backgrounds.
Swiss TPH develops IT solutions for disease prevention.
Improving people’s access to health services.
Veterinary Drugs Against Human Worm Infections
A powerful combination of the standard drug albendazole together with the veterinary drug oxantel pamoate reduces infections with soil-transmitted worms in children. These results obtained in clinical trials promise to relief millions of children in low-resource countries with a cheap and effective deworming therapy.
CLINICAL RESEARCH
Swiss TPH conducts clinical research in low-income countries. As a Contract Research Organisation, it offers clinical research expertise and services to clients from industry, public-private partnerships and academia.
‘WE TACKLE DISEASES THAT DON’T APPEAR PROMINENTLY ON THE RESEARCH AGENDA OF OTHER ORGANISATIONS.’
Christian Burri, Head, Medicines Research
Schoolgirls on Pemba Island waiting to be examined.
Promoting clinical trials with firm scientific and ethical standards
Swiss TPH • Strategic Goals
Medicines Research
With its Department of Medicines Research Swiss TPH acts as an academic Contract Research Organisation (CRO). It plans, manages and monitors clinical trials for the industry, private-public partnerships and academia. The academic profile combined with its long-term experiences in low-resource countries, particularly in Africa, differentiates Swiss TPH from other CROs.
Interdisciplinary clinical research has become a cornerstone at Swiss TPH.
A New Drug Against Sleeping Sickness
In collaboration with the Drugs for Neglected Diseases initiative (DNDi) Swiss TPH dis- covered fexinidazole, a promising new drug against sleeping sickness. The orally active drug kills the parasite Trypanosoma brucei. It is currently undergoing phase III clinical testing in the Democratic Republic of Congo.
Better Diagnosis of Childhood Tuberculosis
Together with partners of the TB Alliance, Swiss TPH developed and assessed a new tuberculosis blood test that provides fast and reliable evidence of the disease in children. The test is a major advance for the diagnosis of childhood tuberculosis, particularly in endemic regions.
Prevent Future Ebola Outbreaks
Swiss TPH monitored two Ebola vaccine trials conducted at the University Hospitals in Lausanne and Geneva. The trials as- sessed the safety and immunogenicity of two different vaccine candidates in healthy volunteers. Based on these results efficacy trials will take place in the affected countries.
Trypanosoma brucei parasites live in the human blood stream.
Tuberculosis trial centre in Bagamoyo, Tanzania
Swiss TPH supervised an Ebola vaccine trial with 100 healthy volunteers.
Medical Services and Diagnostics
The Medical Services and Diagnostics Department serves as the Swiss TPH Travel Clinic and the National Reference Centre for Imported Human Parasitic Diseases. Blood, serum, stool and urine samples are examined with state-of- the-art techniques. Samples originate from hospitals, clinics and laboratories in Switzerland and all over the world.
TRAVEL AND TROPICAL MEDICINE
Swiss TPH is a centre of excellence in travel and tropical medicine and parasitological diagnostic services.
Chronic Disease Clinic Ifakara (CDCI)
The Chronic Disease Clinic Ifakara effectively treats HIV/Aids patients in the Kilombero district in Tanzania. Moreover, it actively pro- motes clinical research and training. More than 6,000 patients are enrolled in a research cohort – a unique opportunity to follow the outcome of antiretroviral therapies. CDCI is a joint effort of Swiss TPH, the University Hospitals of Basel and Bern, the Ifakara Health Institute (IHI), the St. Francis Referral Hospital and the Tanzanian government.
Over 10,000 clients visited the travel clinic and over 25,000 callers sought advice via the service-phone line in 2014.
Travel Clinic
Over 10,000 patients a year seek advice and treatment from the specialists in travel and tropical medicine at our travel clinic in Basel. As the Swiss National Reference Cen-tre for Imported Human Parasitic Diseases, the institute also provides medical advice to hospitals and doctors in Switzerland.
Swiss TPH hosts Switzerland’s second-largest travel clinic.
Swiss TPH • Strategic Goals
Providing pre-travel advice and post-travel
cure
DIAGNOSTICS
Swiss TPH provides fast and reliable diagnosis of human parasitic diseases.
Quality Control for Parasitic Disease Diagnosis
The Diagnostic Team provides many services to Swiss TPH researchers and external partners. Specialists carry out quality control of diagnostic results from clinical studies conducted by Medicines for Malaria Venture (MMV) or they establish field-laboratory settings for Swiss TPH-scientists in Africa or Asia.
Diagnostic Centre
The Diagnostic Centre acts as the Swiss National Reference Centre for Imported Human Parasitic Diseases. It offers a broad range of diagnostic tests covering most parasitic infections, including very rare in- fections. Swiss TPH is one of the few places worldwide able to diagnose the nematode worm gnathostomiasis. Samples arrive from health centres all over the world.
Up to 100 million people worldwide suffer from the threadworm Strongyloides stercoralis.
Specific assays uncover the most important parasitic infections caused by protozoa or helminths.
The Diagnostic Centre detects up to 2 / 3 of all reported malaria cases in Switzerland annually.
‘HIGH-QUALITY DIAGNOSIS OF PARASITIC DISEASES IS NEEDED IN SWITZERLAND AS WELL AS IN TROPICAL COUNTRIES.’
Hanspeter Marti, Deputy Head, Medical Services and Diagnostics
Swiss TPH develops and validates new drugs, vaccines and therapies for poverty-related diseases such as malaria, tuberculosis or Buruli ulcer.
PARASITES AND INFECTIONS
Seals Introduced Tuberculosis to the New World
In an international collaboration Swiss TPH researchers analysed 1,000 years old human skeletons from Peru and isol- ated DNA of seal-specific TB-mycobacteria. The research indicates that seals carried the disease from Africa to Latin America. Exploitation of seals as a dietary staple facilitated the transmission of tubercu- losis from animals to humans.
Swiss TPH explores the molecular basis of infectious diseases.
Phylogenetic tree of all 261 M. tuberculosis lineages
Swiss TPH • Strategic Goals
Linking laboratory
research and field expertise
Swiss TPH is a leading institute in infectious disease research.
‘IT IS NOT SUFFICIENT TO BRING A MEDICATION AGAINST MALARIA TO MARKET AND THEN TO REST ON ONE’S LAURELS. CONTINUOUS EFFORTS ARE NEEDED IN RESEARCHING AND DEVELOPING NEW MALARIA DRUGS.’
Sergio Wittlin, Scientist
Heat Against Buruli Ulcer
Buruli ulcer destroys skin tissue and leaves patients with open sores. Swiss TPH has developed and successfully validated a thermotherapy against this bacterial in- fection. The principle is simple: a heating pad produces enough warmth to kill the bacteria and accelerate wound healing.
Nanoparticles Deceive Malaria Parasites
Swiss TPH malaria specialists and nano- engineers from the University of Basel have designed nanoparticles to mimic the surface of red blood cells. In vitro these particles bind to the malaria parasite Plasmodium falciparum. This interaction might therefore prevent malaria parasites from infecting red blood cells. Nanoparticles show promis-ing potential to stop malaria transmission.
Medical Parasitology and Infection Biology
The Department Medical Parasitology and Infection Biology has a broad and inter- disciplinary scientific expertise in infection and parasite biology. Innovative concepts, methods and ideas are used to under-stand diseases such as malaria, Buruli ulcer, leishmaniasis or helminth infec-tions. Newly gained knowledge is used to develop new drugs and vaccines.
Malaria parasites (yellow) binding to the nanomimics (blue).
Swiss TPH develops therapies against neglected diseases.
Cohorts and Population Studies
SAPALDIA is the largest national population- based cohort study in Switzerland. Running since 1991, it has recorded participants’ state of health, lifestyle and environmental exposures. The blood samples collected are stored in a biobank. They provide a snapshot of each participant’s metabolism at different points in time. Researchers follow an ‘exposomics’ approach to better describe the interactions between environ-mental and genetic factors.
FROM NUMBERS TO PEOPLE
Swiss TPH studies health and disease systems in relation to their molecular, social and ecological environments.
Air pollution increases the risk for diseases and death.
Swiss TPH biobank allows insights into people’s metabolism.
Swiss TPH • Strategic Goals
Translating evidence into
policy and public health action
‘WE DON’T JUST WANT TO LIVE A LONGER BUT A HEALTHIER LIFE.’
Nicole Probst-Hensch, Deputy Head, Depart-ment Epidemiology and Public Health
Better Air for Better Health In 2010 Switzerland introduced a smoking ban in hotels and restaurants. Swiss TPH research showed that this inter-vention significantly improved the heart and lung health of employees working in the hospitality sector.
Health Impact Assessment in Low-Income Countries
Swiss TPH is specialised in health impact assessment (HIA) of large infrastructure projects like dams, mines and plantations in low-income countries. For example, in Sierra Leone, an energy company has devel-oped a 10,000 ha sugarcane estate for the production of ethanol and electricity. Swiss TPH did a longitudinal health study within and outside the project area.
Swiss TPH explores the impact of many environmental exposures ranging from indoor and outdoor air pollution to climate change, electromagnetic fields and noise.
Epidemiology and Public Health
The Department Epidemiology and Public Health analyses disease and health systems in relation to their molecular, social, ecological and cultural environ-ment. Researchers plan and conduct health interventions and assess their impact on human health. The operation of an extensive biobank is one of the department’s key assets. Anonymised biological data and human specimens are stored over decades. These archives allow estimating the impact of genetic, environmental or lifestyle factors on the development of non-communicable diseases.
Passive smoking kills over 600,000 people annually.
Education and training is one of the strategic pillars of the institute. ‘Mutual learning for change’ has been a guiding principle of the institute since its foundation.
MUTUAL LEARNING FOR CHANGE
Unique Learning Experience
As an associated institute of the University of Basel, Swiss TPH offers a unique learning experience in infection biology, epidemi- ology and global health topics. Teachers and instructors are health professionals with long-term experiences in endemic regions. They develop new learning methods, both face-to-face and distance-based, making Swiss TPH appealing for students from all over the world.
Swiss TPH staff provides over 4,000 lecture hours per year.
Swiss TPH • Strategic Goals
Combining research,
training and health
services
E-Learning Courses
Swiss TPH continuously develops new cur-ricula and innovative learning methods. For instance, it designed a new e-learning course on biosafety and biosecurity. In over 20 mod-ules, students learn the essentials on disease transmission and how to respond adequately to disease outbreaks or bioterrorism. The project is a joint undertaking between Swiss TPH, the Robert Koch Institute, Berlin, the Bernhard Nocht Institute for Tropical Medicine, Hamburg, and the African Field Epidemiology Network.
Fruitful Collaborations
‘Learning from each other’ is one of Swiss TPH’s core principles. The institute is engaged in joint PhD programmes with the National University of Singapore, the Novartis Institute for Tropical Diseases and the Biozentrum at the University of Basel, among others. Swiss TPH is a leading force in national and interna-tional teaching networks and projects such as the Swiss School of Public Health (SSPH+) and tropEd, the worldwide network for edu- cation in international health.
Springboard for Careers
Education and training at Swiss TPH prepares students to respond to global health demands. Masters, PhD and postgraduate students learn how to find creative solutions to current and future health challenges. That is how Swiss TPH provides a springboard for careers in academia, national and international organisations, government ministries and the industry.
e-learning is an important complement to traditional learning methods.
About 40 Master and 25 PhD theses are written at Swiss TPH annually.
Lifelong Learning
Swiss TPH is committed to the principle of lifelong learning. It offers tailored courses to specific target audiences such as physi-cians, public health managers, or partners from the industry. Its rich postgraduate education portfolio includes MAS, CAS and DAS programmes in topics ranging from Insurance Medicine and International Health to Clinical Trial Practice and Management.
World Premiere: MBA in International Health Management
Swiss TPH offers a unique MBA in Interna-tional Health Management. The programme goes beyond classical MBAs in health by maintaining a global perspective and an interdisciplinary approach throughout. The 12 modules deal with topics such as ‘Health policy and system’, ‘Health economics and financing’ or ‘Leadership’. Apart from theory and basic concepts, participants learn vari-ous practical skills. They plan and carry out health projects that can be implemented at their workplace or they learn how to increase acceptance towards health programmes through sound marketing and communica-tion strategies.
Teaching and training draws upon Swiss TPH’s excellent research and service performance, guaranteeing an innovative learning experience.
Swiss TPH teaches in three different faculties at the University of Basel (Medicine, Science and Humanities).
TEACHING PORTFOLIO
Undergraduate / BachelorGraduate / Master
Doctorate Professional Postgraduate
• BSc in Biology
• Bachelor of Medicine
• MSc in Epidemiology
• MSc in Infection Biology
• MSc in Infectious Disease, Vaccinology and Drug Discovery
• Master of Medicine
• Master in African Studies
• PhD in Microbiology
• PhD in Cell Biology
• PhD in Zoology
• PhD in Epidemiology
• PhD in Experimental Biomedical Research (MD)
• PhD Platform Health Science (PPHS)
• International PhD in Infection Biology (IPPIB)
• PhD Swiss School of Public Health (SSPH+)
• MBA in International Health Management
• MAS in Versicherungs-medizin – Insurance Medicine
• MAS in International Health
• MAS in Public Health
• DAS in Clinical Trial Prac-tice and Management
• DAS in Health Care and Management in Tropical Countries
• CAS, Allgemeiner Tropenkurs
• CAS in Clinical Research I/II
• CAS in Epidemiologie und Biostatistik
• CAS in Gesundheits-förderung und Prävention
• CAS in Gesundheits- systeme
‘AT SWISS TPH, I DO NOT JUST LEARN FROM A WIDE RANGE OF EXPERTS BUT ALSO FROM MY PEERS.’
Mahy Elaref, patient educator, Egypt
KEY AREAS OF ACTIVITY
Swiss TPH overarches a wide span of health activities pooled into currently 13 key areas of activity. Each area represents a strategically important area of activity in which Swiss TPH contributes to its institutional goals – from innovation to implementation and knowledge transfer.
Preclinical Research and DevelopmentDrugs, vaccines and diagnostics
Clinical Research and DevelopmentTesting and monitoring treatments in low-income countries
Statistical and Mathematical ModellingCapturing complex systems with effective models
Malaria Research and ResourcesResource platform for all malaria-related activities
Basic Research in Infection BiologyInnovative research for poverty-related diseases
Molecular and Genetic EpidemiologyDefining markers for disease control and surveillance
Chronic Diseases and Environmental EpidemiologyTracing environmental factors influencing human health
Society, Culture and Health Societal factors influencing human health
Health in Social-Ecological SystemsAssessing health risks of human activities
Health Systems and PolicySystems thinking for health system strengthening and policy
Sexual and Reproductive Health and Gender Enabling access to sexual and reproductive health
Travel and Tropical MedicineManaging the health risks of tropical diseases
eHealthInformation and communi- cation technologies for better health
Swiss TPH • Key Areas of Act i
vity
Finding new solutions through interdisciplinary
collaboration
PERFORMANCE AND KEY NUMBERS
Swiss TPH is a public organisation, currently receiving 19.5% of its core budget from the cantons of Basel-Stadt and Basel-Land, the University of Basel and the Swiss federal government. The remaining contributions of 80.5% are obtained through competitive funds and the earnings of the Swiss TPH service departments. According to a study of 2014 by the Fachhochschule Nord- westschweiz, Swiss TPH contributes around 46 million CHF gross value added in the Basel area, yearly.
Source: Web of Science, 6 May 2015
Number of Publications 2009 to 2014
Employees and Students 2009 to 2014
0
100
200
300
400
600
500
700
800
2009 2010 2011 2012 20142013
Abroad PhD / Maer udents Employees
450 health specialists and over 140 PhD students currently work at Swiss TPH. Another 100 employees are located in offices abroad in 20 different countries.
Peer-reviewed publications in high impact journals such as New England Journal of Medicine, Lancet, Nature Genetics or PLOS Medicine
0
100
200
300
400
500
2009 2010 2011 2012 20142013
Mandates 31.5%
R. Geigy Foundation 2.2%
Po�graduate Training 2.6%
Medicines Research 3.6%
European Commission 4.1%
SNSF and NCCR 5.8%
Other combined grants 24.8%
Local Government 2.8%
National Government7.6%
University of Basel 9.1%
Medical and Diagno�ic Services 5.9%
Core funding 19.5%
Competitively acquired 80.5%
72 M CHF
Funding 2014
Funding from 2009 to 2014 in Millions CHF
• Bill & Melinda Gates Foundation, US
• Bundesamt für Gesundheit, CH
• Direktion für Entwicklung und Zusammenarbeit, CH
• Drugs for Neglected Diseases initiative DNDi, CH
• European Commission, EU
• Global Fund to Fight AIDS, Tuberculosis and Malaria, CH
Most Important Funding Partners and Clients
• Canton Basel-Stadt, CH
• KfW Bankengruppe, DE
• Schweizerischer Nationalfonds, CH
• Staatssekretariat für Bildung, Forschung und Innovation, CH
• Staatssekretariat für Wirtschaft, CH
• Universität Basel, CH
• World Health Organisation, CH
20132012201120102009
Core funding22%
Core funding18%
Core funding20%
Core funding18%
Core funding17%
2014
Core funding20%
53 56 59 65 72 72
Third party funding and mandates Core funding
Communication and Public AffairsChristian Heuss
Security / BiosafetyMarco Tamborrini
Human Resources: Tobias Schnell
Informatics: Alain Bertolotti
Finances: Martin Näf
Infrastructure: Paul Haas
Project and Grant Service: Michael Käser
AdministrationStefan Mörgeli
Board of Governors
10 members from the Canton Basel-Stadt, the Swiss Federation, universities and the private sector
Chairman: Felix Gutzwiller, Vice-Chairman: Andreas Burckhardt
Directorate
Director: Marcel Tanner (until 30 June 2015) Jürg Utzinger (1 July 2015 onwards)
Department Heads: Nino Künzli*, Nicolaus Lorenz*, Christian Burri, Christoph Hatz, Gerd Pluschke
Administrative Director: Stefan Mörgeli
*Deputy Directors
Teaching and Training, e-learning, Library Head: Axel Hoffmann
Deputy Head: Bernadette Peterhans
ControllingMathias Kronig
Epidemiology and Public Health
Medical Parasitology and Infection Biology
Swiss Centre for International Health
Medicines Research
Medical Services and Diagnostics
ORGANISATIONAL CHART
BiostatisticsPenelope Vounatsou
Chronic Disease EpidemiologyNicole Probst-Hensch
Ecosystem Health SciencesJürg Utzinger
Environmental Exposures and HealthMartin Röösli
Health InterventionsChristian Lengeler
Health Systems Research and Dynamical ModellingTom Smith
Human and Animal HealthJakob Zinsstag
Society, Gender and HealthElisabeth Zemp Stutz
Gene RegulationTill Voss
Helminth Drug DevelopmentJennifer Keiser
Molecular DiagnosticsIngrid Felger
Molecular ImmunologyGerd Pluschke
Molecular Parasitology and EpidemiologyHans-Peter Beck
Parasite ChemotherapyPascal Mäser
Tuberculosis ResearchSébastien Gagneux
Clinical ImmunologyClaudia Daubenberger
Medical ConsultationsJohannes Blum
Travel ClinicChristoph Hatz
Medical Practice FöhreJohannes Blum
Immuno-diagnosticsBeatrice Nickel
National Reference Centre for Diagnostic ParasitologyHanspeter Marti
Clinical ResearchKlaus Reither
Sexual and Reproductive HealthManfred Zahorka
Systems SupportKaspar Wyss
Systems Performance and MonitoringOdile Pham-Tan
Health Technology and TelemedicineMartin Raab
Pharmaceutical MedicineMarc Urich
Research Clus-ter – Academic Clinical Trials and Capacity BuildingChristian Burri
Epidemiology and Public Health
Head: Nino Künzli
Deputy Heads: Nicole Probst-Hensch and Jakob Zinsstag
Medical Parasitology and Infection Biology
Head: Gerd Pluschke
Deputy Head: Sébastien Gagneux
Swiss Centre for International Health
Head: Nicolaus Lorenz
Deputy Head: Kaspar Wyss
Medicines Research
Head: Christian Burri
Medical Services and Diagnostics
Head: Christoph Hatz
Deputy Head: Hanspeter Marti
Sen. Consultant: Johannes Blum
Schützengraben
Spal
ento
rweg
Schützenma�park
1
1/6/8/50
6
30/33
30/33
Brausebad
Schützenma�-�rasse
Universitäts�ital
Bahnhof
Birmannsgasse
Pilger�
rasse
Missions�rasse
Au�rasse
Soci
n�ra
sse
Euler�rasse
Spalenring
Steinenring
Swiss TPHSocin�rasse 57
N
Spalentor
Swiss Tropical and Public Health Institute Socinstrasse 57 CH-4051 Basel
Telephone: + 41 61 284 81 11Fax: +41 61 284 81 01Email: [email protected]
TRAVEL CLINIC
Opening hours: Monday, Tuesday, Thursday 16.00 – 19.00Wednesday, Friday 12.00 – 14.00Without an appointment
Telephone advice:0900 57 51 31 (CHF 2.69 / min fixed net) 8.30 – 11.30 and 14.00 – 17.00
Special consultations: +41 61 284 82 55
Swiss TPH annex buildings
Photography Credits: Swiss Malaria Group, jesmondine / shutterstock, Leonardo da /
Keystone, Martin Ruetschi / Christian Heuss / Wendelin Moser / Science Photo Library /
Thomas Schuppisser / Christian Flierl / Martin Bratschi / Roland Schmid / Joachim Pelikan /
Hanspeter Marti / Klaus Reither / Bernadette Peterhans
Layout and Graphics: Howald Fosco, Basel Print: Gremper AG, Basel
All rights reserved, Swiss TPH, 2015
Swiss TPH’s vision is to improve human health and well-being
through better understanding disease and health systems
and acting on this knowledge.